Published in Cancer Weekly, June 10th, 2008
Previously, Dr. Mielke initiated the ongoing phase II clinical study for ATIR(TM) as principal investigator at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, Maryland,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-06-10)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.